טוען...
Serum sickness with refractory nephrotic syndrome following treatment with rituximab
Rituximab (RTX) is effective for treating childhood refractory nephrotic syndrome (NS), such as steroid-dependent (SD), frequently relapsing (FR), and steroid-resistant (SR) NS. While RTX has been proven to be effective in treating SDNS, FRNS, and SRNS, it may cause serum sickness, a rare illness ch...
שמור ב:
| הוצא לאור ב: | CEN Case Rep |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Japan
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5886928/ https://ncbi.nlm.nih.gov/pubmed/29305810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13730-017-0297-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|